In an association study of the Bal I polymorphism in the dopamine D 3 receptor (DRD3) gene in a French Caucasian population, global comparison of patients with schizophrenia (n = 89, DSM-III-R criteria) and controls (n = 52) led to non-significant differences. However, the homozygosity was significantly more frequent in schizophrenic patients with lifetime substance abuse comorbidity (n = 36) as compared to patients with no history of substance abuse (P = 0.010) or to controls (P = 0.047) and in neuroleptic responder patients as compared to treatment-refractory patients (n = 19; P = 0.037). The combined characteristics treatment response and lifetime substance abuse were strongly associated with homozygosity. We propose that homozygosity for the Bal I polymorphism DRD3 gene is associated with predisposition to substance abuse and/or the pharmacosensitive characteristic of schizophrenia rather than with schizophrenia itself, an hypothesis in agreement with the positive association of this polymorphism with opiate dependence (see companion article by Duaux et al) and the involvement of DRD3 in both pharmacodependence mechanisms and antipsychotic effects of neuroleptics.
The dopamine D 3 receptor (DRD3) is selectively expressed in the mesocorticolimbic dopaminergic system, thought to be implicated in the pathophysiology of schizophrenia, and is a target for both typical and atypical neuroleptics. 1 The DRD3-binding site is increased in post-mortem brains of untreated patients with schizophrenia. 2 A positive association between homozygosity for the Bal I polymorphism at DRD3 gene and schizophrenia has been found in two European independent populations 3 but not replicated in most subsequent studies. The reasons for these discrepancies may lie in the complexity and phenotypic heterogeneity of schizophrenia. 4 A high prevalence (about 30-40%) of lifetime substance abuse exists among patients with schizophrenia, 5 especially in the premorbid phase or during the first years of the disease. 6 Abused substances (alcohol, heroin and cocaine) share the property to unconditionally evoke dopamine release in the shell of nucleus accumbens, 7 where DRD3 is selectively expressed. 1 In addition, pharmacological evidence in rats 8 and monkeys 9 suggests that DRD3 mediates reinforcing effects of psychostimulants. Moreover, DRD3 binding is elevated in the post-mortem human brain from cocaine overdose victims. 10 Therefore, the DRD3 gene appears as a candidate gene not only for schizophrenia, but also for alcoholism and/or drug addiction, in which the influence of genetic factors has also been established. 11 Association studies in alcoholism have led to contradictory results [12] [13] [14] but, in an accompanying paper, homozygozity at the DRD3 gene Bal I polymorphism was associated with opiate abuse. 15 The present study reports a positive association of homozygozity of DRD3 gene at Bal I polymorphism in a French sample of schizophrenic patients with current or past substance abuse comorbidity and in patients who respond to neuroleptic treatment.
Eighty-nine unrelated in-or out-patients with schizophrenia (n = 83) or schizo-affective disorder (n = 6, DSM-III-R criteria, APA 1987) and fifty-two unrelated controls, mostly from medical staff, with no personal and/or familial psychiatric or substance abuse history, as assessed with a semi-standardized interview (see Methods), were recruited from a French Causasian population. Patients who had at least once in their life fulfilled the DSM-III-R criteria for abuse and/or dependence on any kind of psychoactive substance except nicotine (but not occasional users) were defined as 'substance-abusing' patients (see Table 1 , n = 36). Nineteen patients had abuse of or dependence on more than one substance, alcohol and/or cannabis being the most frequent. Patients with no clinical remission despite several trials with different neuroleptics for a sufficient duration and requiring permanent day care were defined as 'treatment refractory' patients, while the remaining patients, who at least partly responded to neuroleptics were defined as responders.
Genotype distributions in either controls or patients did not depart from the Hardy-Weinberg equilibrium. The total sample of schizophrenic patients (n = 89) did not significantly differ from controls (n = 52) with regard to allele frequencies ( . This is in contrast to previous studies, 17 and one cohort of Ref. 18 . 18 Although the different substances of abuse differ in their clinical features, we took here into account any lifetime substance abuse or dependence (DSM-III-R criteria), sometimes lasting for no more than a few months, as a marker of a reward system dysfunction. Although a falsely positive association cannot be ruled out in this sample of limited size, our result is consistent with the excess of homozygotes at the DRD3 gene in non schizophrenic substance abusers reported in an accompanying paper 15 and in one cohort of Ref. 19. 19 It is also in agreement with a role of DRD3 in drug abuse or dependence evidenced in pharmaco- Table 2 Allele and genotype frequencies and counts for patients with schizophrenia and controls
Genotypes
Gentoypes logical studies in animals 8, 9 as well as in a human postmortem study. 10 Treatment-responder schizophrenic patients differed significantly as compared to treatment-refractory patients in genotype distribution ( 2 = 5.76, d.f. = 1, P = 0,016, Table 2 ) and higher frequency of homozygosity ( 2 = 4.37, d.f. = 1, P = 0.037), but no significant excess of genotype 1-1 or allele 1 frequency were observed. Comparisons of treatment-responders to controls did not show any significant difference. These results are in agreement with two previous studies, 17, 20 although not always replicated. 18, [21] [22] [23] [24] [25] [26] The various criteria used to define treatment efficacy in these previous reports could at least partly explain the discrepancies. Definition of treatment response can rely on persistence of positive or negative symptoms, percentage of improvement on symptomatic scales, ability for reinsertion and/or election for clozapine therapy; leading to distinct clinical subgroups, whose relevance with regard to underlying physiopathological processes is questionable. In contrast, treatment-refractory patients, without any clinical remission and under permanent day care
27 may correspond to a more severely ill cluster of patients, showing distinct clinical features (prevalence of negative symptoms, importance of cognitive dysfunction, pre-treatment neurological dysfunction), outcome (early age-of-onset, chronic evolution), neuroradiological abnormalities, with possible minimal organic brain damage and distinct aetiologic background not implicating dopamine systems.
Since there is some clinical evidence that drug intake could be used by schizophrenic patients as automedication preceding any neuroleptic treatment, 6 in exploratory analyses we compared the genotype distribution for the DRD3 gene Bal I polymorphism with regard to the two clinical features of schizophrenia: substance abuse lifetime comorbidity and sensitivity to treatment (Table 3) . Although there was no significant difference in the distribution of treatment-responders between the two subgroups: substance-abusing patients and those with no history of substance abuse, highly significant differences were seen in genotype distribution ( .f. = 1, P = 0.031), as compared to treatment-refractory patients with no history of substance abuse. Although obtained in a limited sample, this suggests that homozygosity could be associated with a common trait underlying both substance abuse predisposition and treatment-response in schizophrenic patients, possibly distinctive of a pharmacosensitive form of schizophrenia. This is consistent with the idea that DRD3 represents an important target for both neuroleptics and abused drugs.
A puzzling question remains the meaning of an association of a disease with homozygosity for either allele. Previous reports showed an association between schizophrenia and homozygosity for Bal I polymorphism at DRD3 gene, sometimes with an excess of genotype 1-1, in a few reports with an increase of genotype 2-2, however in ethnically different populations. 16 It thus appears that the excess of homozygosity of either allele in substance-abusing and/or in treatment responder schizophrenic patients is more robust than the excess of genotype 1-1. Moreover, the excess of 1-1 genotype among homozygotes might only reflect the higher frequency of allele 1 as compared to allele 2 in the European Caucasian population. If true, excess of homozygosity in substance-abusing schizophrenic patients is more consistent with the observation of an excess of homozygosity in non-schizophrenic opiatedependent patients. The mechanisms by which homozygosity for any allele of one gene can predispose to a disease remain unknown. Deletion of the DRD3 gene region that is amplified during genotyping could result in apparent homozygosity and dysfunction of the gene. On the other hand, homozygosity conferring an increased risk has already been reported: the relative risk for sporadic Creutzfeldt-Jakob disease was found to be higher in homozygotes for either allele at codon 129 of the prion protein. 28 After numerous studies with contradictory results, the role of the DRD3 gene in the predisposition to schizophrenia remains controversial. Though there is no support for a major role, replication of positive studies in independent populations and large meta-analysis suggest either a minor effect or an effect in subgroups of patients. We propose that homozygozity for the DRD3 gene, rather than playing a direct role in the susceptibility to schizophrenia itself, could be related to a particular sensitivity to pharmacological agents acting on dopaminergic systems. This sensitivity could be found in schizophrenia, as well as in drug abuse. The larger proportion of drug abusers among patients with schizophrenia as compared to the general population may explain the previously reported association between DRD3 and schizophrenia.
Materials and methods

Subjects and psychiatric assessment
Eighty-nine (55 males; 34 females) unrelated patients with schizophrenia (n = 83) or schizo-affective disorder (n = 6) were examined by trained psychiatrists with a semi-standardized interview (SADS-LA lifetime version anxiety version-revised, French translation 29 ) leading to lifetime diagnosis according to DSM-III-R criteria (APA, 1987). In addition, information concerning clinical and treatment history and familial history of psychiatric disease were obtained from medical staff of our hospital or from previous hospitalizations, ambulatory private psychiatrists, review of case notes and, whenever possible, information from the family. Each clinical record was checked by a second psychiatrist and discrepancies were further documented to reach consensus. An OPCRIT 3.3 checklist was completed. Psychiatric assessment also included evaluation of the course of illness (mean duration of the disease ± s.d. = 11.28 ± 8.51 yrs), current symptomatology with Positive and Negative Syndrome Scale (PANSS 30 : total score : 80.7 ± 18 (mean ± s.d.)) global severity (Clinical Global Impression-severity, CGI = 4.98 ± 0.77 (mean ± s.d.)) and functional disability (Global Assessment Scale, GAS: 40.7 ± 6 (mean ± s.d.)). The scale proposed by May et al 27 (rated from 1 to 6) was used to evaluate the response to medication, on the basis of rapidity and quality of symptom remission, necessity for prolonged hospitalization, ability for autonomy and social rehabilitation. Treatment refractory patients had a score of at least 5 (no clinical remission despite several trials with different neuroleptics for a sufficient duration and necessity for permanent day care). Former or current substance abuse and/or dependence on any kind of psychoactive substance including alcohol or tranquillizers but not nicotine (see Table 1 ) were systematically screened and patients who had at least once in their life fulfilled the DSM-III-R criteria for abuse or dependence (but not occasional use) were defined as 'substance-abusing'. In four patients only, substance abuse preceded psychotic or prodromal symptoms, as assessed by retrospective interview. However, in every case, substance-induced psychosis could be eliminated (in one case substance was ether, but with an abuse of limited duration and severity, in the three remaining cases, alcohol alone and/or cannabis was moderately abused).
The fifty-two unrelated controls (26 males, 26 females), mostly from medical staff were screened for no personal and/or familial psychiatric or substance abuse history with a semi-standardized interview (SCID-NP) and additional questions about family history (first and second degree relatives). Patients did not differ significantly from controls with regard to gender distribution (P = 0.17) or ages (schizophrenic patients: 33.3 ± 9.2 (mean ± s.d.) and controls: 35.47 ± 10).
All subjects but four (two patients and two controls) had at least three French Caucasian grandparents (with the possibility of one grandparent originating from another country of Western Europe, except two patients with one grandparent of Caribbean origin). The results were unchanged when excluding those six subjects. The psychiatric assessment was completed before genetic analysis and the choice for analysis factors was done blind to the genotyping results. This study received the agreement of the local Ethical Committee. All subjects gave their written informed consent prior to the study.
DNA analysis
Venous blood samples were collected in ethylenediaminetetracetic acid-containing tubes. Genomic DNA was extracted from peripheral leukocytes and amplified by Polymerase Chain Reaction (PCR), as described, 31 with primers flanking exon 1 (5Ј-GCT CTA TCT CCA ACT CTC ACA-3Ј; 5Ј-AAG TCT ACT CAC CTC CAG GTA-3Ј) and thermostable Taq Polymerase (AmpliTaq, Perkin Elmer Cetus, Forest City, CA, USA). PCR products (242 bp) were digested by Msc I (an isoschizomere of Bal I) restriction enzyme before agarose gel electrophoresis and staining with ethidium bromide. Besides constant bands of 111 bp and 47 bp, the presence of a 304-bp band denoted a 1-1 homozygosity, bands of 206 and 98 bp a 2-2 homozygosity and bands of 304, 206 and 98 bp heterozygosity. Genotyping was carried out blind to the clinical status of individuals and was at least duplicated.
Statistical analysis
Genotype distribution was compared to predictable value from Hardy-Weinberg equilibrium. Two-tailed comparisons of genotypes, allele frequency, homozygosity or heterozygosity were performed with 2 test. Yates-corrected 2 was used when expected values of tables were less than 5. Pairwise comparisons of subgroups were performed when three-way 2 reached the level for significance. Corrections for multiple testing (Bonferroni) were not applied because analyses were either replications of previously published findings (schizophrenia with regard to response to treatment) or of exploratory nature (substance-abusing patients with schizophrenia).
